Company Overview of MSD K.K.
MSD K.K. develops, manufactures, and sells pharmaceutical products in Japan. It offers prescription drugs and vaccines in various therapeutic areas, including cardiovascular, respiratory, hepatitis, bone and skin diseases, central nervous system, anesthesiology, cancer, women’s health, and ophthalmic diseases. MSD K.K. was formerly known as Banyu Pharmaceutical Co., Ltd. and changed its name to MSD K.K. in October 2010. The company was founded in 1915 and is headquartered in Tokyo, Japan. MSD K.K. operates as a subsidiary of Merck & Co. Inc.
Founded in 1915
Key Executives for MSD K.K.
President and Representative Director
Senior Vice President, Head of Administration Division and Executive Director
Senior Vice President and Head of Marketing & Sales Division
Deputy Head of Production Division
Compensation as of Fiscal Year 2015.
MSD K.K. Key Developments
MSD Submits New Drug Application for Antiallergic Agent, Desloratadine to be Co-Marketed with Kyorin
Oct 15 15
MSD K.K. submitted a new drug application for an antiallergic agent, desloratadine (generic name). In November 2014, MSD, through its affiliate, signed a co-marketing agreement in Japan for desloratadine with Kyorin Pharmaceutical Co. Ltd. With the agreement, MSD and Kyorin will be co-marketing desloratadine after its approval and launch. Desloratadine is a novel and second generation histamine H1-receptor antagonist. While it is under NDA review in Japan for the indications of allergic rhinitis, hives, and itching resulting from skin diseases (eczema/dermatitis, pruritus cutaneous), desloratadine has already had approved in more than 120 countries including the United States and Europe. MSD is committed to the improvement of QOL of Japanese people by developing and delivering innovative medicines. This NDA submission reflects the company's commitment demonstrated in the respiratory and allergic disease areas.
Astellas Pharma, Inc. and MSD K.K. Announce Availability of Diabetes Drug in Japan
Apr 18 14
Astellas Pharma, Inc. and MSD K.K. have announced the availability of Suglat tablets 25mg and 50mg for the indication of type 2 diabetes in Japan. Suglat Tablets is a selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor discovered through a research collaboration and is being jointly developed by Astellas and Kotobuki Pharmaceutical Co. Ltd. SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Suglat Tablets reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. Suglat Tablets is the first SGLT2 inhibitor approved as a treatment for type 2 diabetes in Japan. Astellas will manufacture and sell Suglat Tablets and co-promote it with Kotobuki and MSD.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries